Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

Volume: 15, Issue: 1, Pages: 37 - 37
Published: May 16, 2018
Abstract
Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase (IN) and have been shown to potently inhibit infection by wild-type HIV-1. Of the three current FDA-approved INSTIs, Dolutegravir (DTG), has been the most effective, in part because treatment does not readily select...
Paper Details
Title
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Published Date
May 16, 2018
Volume
15
Issue
1
Pages
37 - 37
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.